4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of high-density lipoprotein (HDL) has been observed. Although the actual players are unknown, anti-HDLs were associated with altered lipid profile, decreased paraoxonase 1 (PON1) activity and CV disease in RA. Therefore, we aimed to evaluate whether the presence of antibodies against PON1 may be involved in this scenario. IgG anti-PON1 antibodies were quantified by ELISA in serum samples from 212 RA patients, 175 healthy controls (HC) and 54 subjects with traditional CV risk factors (CVR). A subgroup of 13 RA patients was prospectively followed upon tumour necrosis factor-α  (TNFα) blockade. Serum PON1 activity, nitric oxide (NO) and total antioxidant capacity (TAC) were measured. Interferon-γ (IFNγ), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule (sICAM) and TNFα serum levels were assessed by immunoassays. PON1 rs662 (Q > R) status was studied by reverse transcription (RT)-PCR. IgG anti-PON1 antibodies are increased in RA patients compared with HC (P<0.0001) and CVR subjects (P<0.001), even after correcting for total IgG levels. Although no associations with lipid profile were found, a positive correlation with Health Assessment Questionnaire (HAQ) was observed (r=0.215, P=0.004). Anti-PON1 antibodies were associated with PON1 activity, NO and TAC, a rs662-mediated gene-dosage effect being found. Similarly, anti-PON1 antibodies were associated with sICAM serum levels in univariate and multivariate models. Finally, these antibodies were not affected by TNFα blockade. Anti-PON1 antibodies can be responsible for PON1 impairment in RA patients, with a potential impact on biomarkers of oxidative status and endothelial activation. A gene-environment interaction of rs662 variants is supported.

          Related collections

          Author and article information

          Journal
          Clin. Sci.
          Clinical science (London, England : 1979)
          Portland Press Ltd.
          1470-8736
          0143-5221
          November 01 2016
          : 130
          : 21
          Affiliations
          [1 ] Area of Immunology, Department of Functional Biology, University of Oviedo, 33006 Asturias, Spain Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias (IPLA-CSIC), 33300 Asturias, Spain.
          [2 ] Department of Rheumatology, Hospital Universitario Central de Asturias, 33011 Asturias, Spain.
          [3 ] Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain.
          [4 ] Area of Immunology, Department of Functional Biology, University of Oviedo, 33006 Asturias, Spain.
          [5 ] Centro de Salud Sariego, Servicio de Salud del Principado de Asturias, 33518 Asturias, Spain.
          [6 ] Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain Department of Medicine, University of Cantabria, 39011 Santander, Spain Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 2193 Johannesburg, South Africa.
          [7 ] Area of Immunology, Department of Functional Biology, University of Oviedo, 33006 Asturias, Spain anasua@uniovi.es.
          Article
          CS20160374
          10.1042/CS20160374
          27520507
          69299f86-0ed7-4515-a494-8b18dc39d16e
          History

          paraoxonase,rheumatoid arthritis,anti-paraoxonase 1 antibodies,cardiovascular disease,high-density lipoproteins

          Comments

          Comment on this article